Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.83 |
| ▸ | MAPT | P10636 | 2/20 | 0.83 |
| ▸ | MEN1 | O00255 | 2/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.83 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.83 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.83 |
| ▸ | SQLE | Q14534 | 6/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | FNTA | P49354 | 1/20 | 0.52 |
| ▸ | FNTB | P49356 | 1/20 | 0.52 |
| ▸ | ICMT | O60725 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Geraniol SCHEMBL20481371 | 0.98 | KMT2A (0.83) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Geraniol SCHEMBL3188016 | 0.98 | KMT2A (0.83) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL16664315 | 0.91 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL7944378 | 0.91 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Geranylgeraniol SCHEMBL127330 | 0.91 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Geranylgeraniol SCHEMBL23814969 | 0.91 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Farnesol SCHEMBL7546574 | 0.91 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL4717874 | 0.91 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Geranylgeraniol SCHEMBL16664300 | 0.91 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Solanesol SCHEMBL4762223 | 0.91 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222606-A1 | METHOD FOR PRODUCING BISABOLOL WHICH IS FARNESOL FREE OR IS LOW IN FARNESOL | BASF SE (DE) | 2010-09-02 | — | — | US | claimed |
| US-9199900-B2 | Method for converting farnesol to nerolidol in the presence of alpha-bisabolol | SYMRISE AG (DE) | 2015-12-01 | — | — | US | disclosed |
| US-20130289317-A1 | Method for Converting Farnesol to Nerolidol in the Presence of Alpha-Bisabolol | SYMRISE AG (DE) | 2013-10-31 | — | — | US | disclosed |
| US-20100222606-A1 | METHOD FOR PRODUCING BISABOLOL WHICH IS FARNESOL FREE OR IS LOW IN FARNESOL | BASF SE (DE) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289317-A1 | Method for Converting Farnesol to Nerolidol in the Presence of Alpha-Bisabolol | FNTB, FNTA, FHIT | KMT2A 4266/4885MAPT 2133/4885MEN1 491/4885 |
| US-20100222606-A1 | METHOD FOR PRODUCING BISABOLOL WHICH IS FARNESOL FREE OR IS LOW IN FARNESOL | FHIT, FDPS, FNTA | KMT2A 4087/4885MAPT 1980/4885MEN1 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.